Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
Top Cited Papers
- 10 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 116 (2) , 180-187
- https://doi.org/10.1161/circulationaha.106.668020
Abstract
Background— An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that require long-term anticoagulation. Rivaroxaba...Keywords
This publication has 24 references indexed in Scilit:
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Selection of the optimal reperfusion strategy for STEMI: does time matter?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.European Heart Journal, 2006
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogsXenobiotica, 2005
- Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administrationJournal of Thrombosis and Haemostasis, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Hepatic Findings in Long-Term Clinical Trials of XimelagatranDrug Safety, 2005
- Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low‐molecular‐weight heparins: a meta‐analysisJournal of Thrombosis and Haemostasis, 2004
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluationJournal of Thrombosis and Haemostasis, 2004
- Epidemiology and Costs of Venous Diseases in Central ItalyAngiology, 1997